Whitepaper: Accelerate antibody screening and characterisation

Posted: 24 August 2021 | | No comments yet

This whitepaper overviews use of Advanced Flow Cytometry to accelerate antibody screening and characterisation and reveal deeper biological insights.

The iQue® Advanced Flow Cytometry Platform is designed specifically for high-throughput, large-scale screening, hence is the ideal platform for antibody discovery workflows.

This white paper reviews how biopharmaceutical companies, Takeda Pharmaceuticals, Avacta Life Sciences, AbX Biologics and Ablynx, (a Sanofi company), are using the iQue® Advanced Flow Cytometry Platform for high throughput antibody screening and characterisation workflows.

    To read this whitepaper in full, please complete the form below:


    By clicking submit you confirm that you accept our terms and conditions and privacy policy.